Navigation Links
Genetic variation in East Asians found to explain resistance to cancer drugs
Date:3/18/2012

DURHAM, N.C., AND SINGAPORE A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

Tyrosine kinase inhibitor drugs (TKIs) work effectively in most patients to fight certain blood cell cancers, such as chronic myelogenous leukemia (CML), and non-small-cell lung cancers (NSCLC) with mutations in the EGFR gene.

These precisely targeted drugs shut down molecular pathways that keep these cancers flourishing and include TKIs for treating CML, and the form of NSCLC with EGFR genetic mutations.

Now the team at Duke-NUS Graduate Medical School in Singapore, working with the Genome Institute of Singapore (GIS), Singapore General Hospital and the National Cancer Centre Singapore, has discovered that there is a common variation in the BIM gene in people of East Asian descent that contributes to some patients' failure to benefit from these tyrosine kinase inhibitor drugs.

"Because we could determine in cells how the BIM gene variant caused TKI resistance, we were able to devise a strategy to overcome it," said S. Tiong Ong, M.B.B. Ch., senior author of the study and associate professor in the Cancer and Stem Cell Biology Signature Research Programme at Duke-NUS and Division of Medical Oncology, Department of Medicine, at Duke University Medical Center.

"A novel class of drugs called the BH3-mimetics provided the answer," Ong said. "When the BH3 drugs were added to the TKI therapy in experiments conducted on cancer cells with the BIM gene variant, we were able to overcome the resistance conferred by the gene. Our next step will be to bring this to clinical trials with patients."

Said Yijun Ruan, Ph.D., a co-senior author of this study and associate director for Genome Technology and Biology at GIS: "We used a genome-wide sequencing approach to specifically look for structural changes
'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Rare genetic disorder gives clues to autism, epilepsy, mental retardation
2. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
3. Study finds genetic variant plays role in cleft lip
4. Genetic finding implicates innate immune system in major cause of blindness
5. American College of Medical Genetics receives $13.5M NIH contract
6. Clue to genetic cause of fatal birth defect
7. Can genetic information be controlled by light?
8. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
9. Modern genetics vs. ancient frog-killing fungus
10. Genetic based human diseases are an ancient evolutionary legacy
11. Genetic evidence for avian influenza movement from Asia to North America via wild birds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... may one day reap the benefits of research at the ... can be used to make new tendon or ligament tissue. ... challenge to orthopedic medicine. In the United States, at ... Moreover, the intervertebral disc, which is composed in part of ...
... activity of a key brain cell receptor involved in ... mice engineered to have pathological hallmarks of the disease. ... the pathologies--the brain-clogging buildup of protein "amyloid plaque" outside ... cells. , In an article in the March ...
... to neural stem cells derived from bone marrow, researchers ... developed a tool to track and kill malignant brain ... , Results of an animal study are published in ... the researchers are now applying to regulatory agencies to ...
Cached Biology News:Stem cells can repair torn tendons or ligaments 2Experimental drug reverses key cognitive deficits, pathology in Alzheimer's 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3
(Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... CanDiag, Inc., a University of North Carolina at ... to OncoTab, Inc. , “The new name is ... said CEO and Chief Science Officer, Dr. Pinku Mukherjee, ... diagnostics to include imaging and therapies, and our new ... in 2011 by Dr. Mukherjee, an Irwin Belk Endowed ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... Conference at 2:10 PM ET on Tuesday, December 13, ...
... Conn., Dec. 6, 2011 Biodel Inc. (Nasdaq: ... ended September 30, 2011. Fourth Quarter Operating ... 2011, the company: Selected a new lead ... a Phase 1 clinical trial; Extended an agreement with ...
... Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive ... be held on December 13-14, 2011 in New York.  ... scheduled to present an overview of the Company on ... A live webcast and subsequent archived replay ...
Cached Biology Technology:Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 6Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011 2
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Phospho-Btk (Tyr223) Antibody...
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
UBC13 Antibody...
Biology Products: